Originally published as JHC exPRESS on November 11, 2008. doi:10.1369/jhc.2008.952911
Volume 57 (3): 257-264, 2009 Copyright ©The Histochemical Society, Inc. Choice of Fixative Is Crucial to Successful Immunohistochemical Detection of Phosphoproteins in Paraffin-embedded Tumor Tissues
Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania Correspondence to: Zhi-Qiang Zhang, MD, PhD, Department of Biologics Research, Merck Research Laboratories, West Point, PA 19486. E-mail: zhiqiang_zhang{at}merck.com
Protein phosphorylation is frequently used as an indicator of cellular signaling activity. Elevated phosphorylation of tyrosine kinase receptors plays an important role in cancer pathogenesis. However, phosphoproteins are usually poorly preserved in clinical tissue samples that are routinely fixed in 10% formalin. Nonetheless, in oncology clinical trials, use of phosphoproteins as biomarkers has been considered to be of great value in evaluating the effectiveness of a given drug candidate. Therefore, it is worthy of investigating whether alternative fixatives would improve the preservation of phosphoproteins in tissue. We compared the IHC staining of a number of phosphoproteins in xenograft and human surgical tumor tissues fixed in three different fixatives: 10% formalin, 4% paraformaldehyde (PFA), and Strecks tissue fixative (STF). We found that STF significantly enhanced the staining intensity of phosphoproteins compared with 10% formalin or 4% PFA. STF fixative also showed superiority of preservation of phosphoproteins in human surgical samples. Our results indicate that the choice of fixative could significantly affect the usability of clinical tissue samples for evaluating phosphoprotein by IHC. (J Histochem Cytochem 57:257–264, 2009)
Key Words: fixative Strecks tissue fixative phosphoprotein tumor tissues paraffin tissue section
CELL-TO-CELL COMMUNICATION through signaling between growth factors, and their respective receptors, is essential for living tissues to maintain proper tissue structure and function (Weinberg 2007
Formalin, a commonly used fixative for tissue samples in pathology laboratories, is capable of forming cross-links with proteins, preventing cellular distortion and loss of chemical activity in the tissue, thus contributing to excellent preservation of cellular antigenicity (Warmington et al. 2000
Many previous studies have looked at the effect of other fixatives on total protein in comparison to 10% formalin; however, these studies did not focus on phosphoproteins (Beckstead 1994
Xenograft Tumor Samples Six-week-old, female NCr nude mice (Taconic; Germantown, NY) were implanted subcutaneously in the right flank with 1 x 107 SKOV-3, Geo, HT-29, and A549 cells suspended in 0.2 ml of Hanks buffered salt solution (Invitrogen; Carlsbad, CA); Caco-2 cells were suspended in Matrigel (BD Biosciences; San Jose, CA) and implanted similarly. Tumor development was monitored regularly. Tumor weight was estimated using a predefined formula of length x width x height, and tumors were harvested when the estimated weight reached 250 mg. All animal experiments were performed under an Institutional Animal Care and Use Committee (IACUC)-approved protocol at Merck and Co. (West Point, PA). Five types of xenograft tumor tissues (SKOV-3, Caco-2, Geo, HT-29, and A549) were harvested and divided into three equally sized pieces immediately after removal from the mouse. The samples were fixed in STF (Streck Laboratories; Omaha, NE), 10% neutral buffered formalin (10% formalin; ThermoFisher, Pittsburgh, PA), or 4% PFA (Boston BioProducts; Boston, MA) for 16–24 hr. The xenograft tumors were processed with 70% ethanol, 95% ethanol, 100% ethanol, xylenes, and paraffin in a tissue processor (Sakura; Torrance, CA). The xenograft tumors were embedded in paraffin, cut into 5-µm sections, and mounted onto Superfrost plus glass slides (ThermoFisher).
Human Surgical Tumor Samples
IHC
To confirm the specificity of phosphoprotein staining, lambda phosphatase was applied on the sections before incubation with primary antibodies. Briefly, after peroxidase activity was blocked, the sections were washed with distilled water and incubated with lambda phosphatase (New England BioLabs; Ipswich, MA) diluted in reaction buffer plus MnCl2 at 10,000 U/ml and 50,000 U/ml and incubated at 37C for 60 min. The incubation was done in separate slide chambers to prevent cross-contamination of the phosphatase with the primary antibody and reaction buffer-only controls. Sections were washed with distilled water several times, and the procedure continued with the addition of primary antibody as above.
Scoring System and Statistics
One-way ANOVA with Friedmans test and Dunns multiple comparison post-test was used to compare the scoring results of xenograft tumor tissues fixed with STF, 10% formalin, and PFA. Wilcoxon matched-pairs test was used to compare the human surgical tumor samples fixed in STF and 10% formalin (GraphPad Prism version 5.01 for Windows; GraphPad Software, San Diego, CA). p<0.05 for both tests was considered significant.
Effect of Different Fixatives on Preservation of Phosphoproteins in Xenograft and Human Surgical Tumor Samples Overall, the staining intensity of nearly all antibodies was significantly higher in STF-fixed tissues than in 10% formalin– or 4% PFA–fixed tissues. The staining intensity of STF-fixed tissues was significantly higher in 60% (6/10) of the antiphosphoprotein antibodies tested for all types of xenograft tumor tissues (Table 2 ). For instance, pMET staining (Figure 2A ) was scored as +++ for all STF-fixed tissue samples but was only scored as + for the majority of 10% formalin– or 4% PFA–fixed tissues (p=0.0008). Similar results were observed in pEGFR, pHER2, pHER3, pHER4, and pTyr (Table 2). Surprisingly, pEGFR was essentially undetectable in all 10% formalin– and 4% PFA–fixed tissues, except for SKOV-3. In contrast, all STF-fixed tissues had detectable pEGFR, with scores ranging from + to +++. For pIGF-1R/IR and pMAPK, there was a trend that STF-fixed tissues had stronger staining than 10% formalin– or 4% PFA–fixed tissues, although not statistically significant. Interestingly, the preservation of nuclear phosphoproteins, such as pp53 and pAkt, was not significantly affected by the selected fixatives. Overall, 10% formalin–fixed tissues had slightly higher staining intensities compared with 4% PFA–fixed tissues, although not statistically significant.
In human postoperative surgical samples (Table 3 ; Figure 2B), the majority of phosphoproteins were undetectable in all five 10% formalin–fixed tumor tissue samples, with the exception of pMAPK and pp53. In contrast, STF-fixed lung tumor tissue was positive for nearly all phosphoproteins except for pAkt. Moreover, the staining intensity of pp53 and pHER4 (Figure 2B) was significantly higher in STF-fixed tissues, except one breast tumor tissue with +++ scores. Taken together, for preservation of phosphoproteins in xenograft tumor tissues as well as in clinical surgical tumor samples for IHC detection, STF is clearly shown as a better choice of fixative compared with 10% formalin and 4% PFA.
Heterogeneous Staining Pattern of Phosphoproteins in Tissue Section We observed a consistent heterogeneous staining pattern of the antiphosphoprotein antibodies in the xenograft and human surgical tumor samples used in this study, regardless of fixative. The staining intensity of phosphoproteins was generally higher in the area closer to the tissue surface and gradually decreased toward the center (Figure 3 ). The membranous phosphoproteins showed no staining in the center of tumor tissues, whereas a nuclear phosphoprotein (pp53) showed weaker staining in the same area. To confirm whether the staining pattern was phosphoprotein specific, sections of the SKOV-3 xenograft tumor were incubated with lambda phosphatase before addition of primary antibodies. We found that 10,000 or 50,000 U/ml of lambda phosphatase was sufficient to completely eliminate the positive staining in both STF- and formalin-fixed tissue sections. These results indicate that protein dephosphorylation after tissue removal from the body occurs so rapidly that penetration of fixative into the tissues can only preserve portions of phosphoproteins that are close to the tissue surface. Thus, it is likely that fixatives that are capable of faster and deeper penetration into tissue would be very helpful in uniformly preserving phosphoproteins in tissues.
Effect of Fixatives and Storage Condition on Stability of Tissue Phosphoproteins Choice of fixative and storage condition and time of precut unstained tissue section all play an important role in preservation of antigens in paraffin-embedded tumor tissues (Jacobs et al. 1996
Preservation of phosphoproteins in tissues by conventional fixatives, such as 10% formalin, has proven to be challenging, especially for clinical postoperative tissue samples (Baker et al. 2005
In a typical clinical setting, however, it may not be practical to collect and fix the surgical tissue samples in a timely fashion. Therefore, alternative fixatives that can penetrate into tissues more quickly than 10% formalin were examined to address this critical issue. STF is a non–cross-linking fixative that has been suggested in a number of previous studies as a better choice for IHC detection of total proteins in tissues compared with 10% formalin and 4% PFA (Prento and Lyon 1997 In this study, it was frequently observed that the staining intensity of phosphoproteins near the tissue surface was generally higher than toward the center of the tissue, regardless of fixative, in both xenograft and human tumor tissues. The specificity of these heterogeneous staining patterns was confirmed by morphological characteristics of staining patterns of different antibodies, such as membranous staining for anti-pMet, pIGF-1R/IR, pEGFR, pHER2, pHER3, and pHER4 and nuclear and cytoplasmic staining for anti-pAkt, pMAPK, and pp53 antibodies. In addition, staining specificity was confirmed by phosphatase digestions of tissues before application of primary antiphosphoprotein antibodies (Figure 3). The heterogeneous staining pattern from perimeter to center once again indicates the instability of the phosphoproteins. It is likely that fixatives begin to work on penetration of the outermost tumor tissue area, and penetration of fixative into deeper areas of the tissue takes more time, whereas dephosphorylation is rapidly ongoing. This may be a possible reason for no or weaker staining of phosphoproteins in the center of the tissue. Therefore, a combination of a better fixative and quick time to fixation is critical for successful preservation of phosphoproteins in clinical tissue samples.
We thank Jon Stek of the Department of Medical Communication at Merck & Co., for his careful language editing of the manuscript.
Received for publication September 25, 2008; accepted October 30, 2008
Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, et al. (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110–124 Atkins D, Reiffen K-A, Tegtmeier CL, Winther H, Bonato MS, Storkel S (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52:893–901 Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G (2005) Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 11:4338–4340 Beckstead JH (1994) A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues. J Histochem Cytochem 42:1127–1134[Abstract] Blow N (2007) Technology feature: tissue preparation. Nature 448:959–962[Medline] Chan ASY, Cheung KN, Chiu KY (1994) KP1 immunohistochemical demonstration of macrophages in colorectal tissues: effects of different fixatives and different fixation times. J Histotechnol 17:329–332 DiVito KA, Charette LA, Rimm DL, Camp RL (2004) Long-term preservation of antigenicity on tissue microarrays. Lab Invest 84:1071–1078[CrossRef][Medline] Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, et al. (2003) Prognostic significance of phosphorylated p38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100:499–506 Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, Cedres S, et al. (2008) A phase II pharmacodynamic study of Erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 14:3867–3874 Fergenbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME (2004) Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 13:667–672 Guix M, Granja Nd M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, et al. (2008) Short preoperative treatment with Erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 26:897–906 Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ (1996) Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 88:1054–1059 Jones RJ, Boyce T, Fennell M, Jacobs V, Pinto F, Duffield E, Clack G, et al. (2008) The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemother Pharmacol 61:23–32[CrossRef][Medline] Lim J, Kin J-H, Paeng J-Y, Kim M-J, Hong S-D, Lee J-I, Hong SP (2005) Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 58:1199–1205 Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, et al. (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65:1479–1488 Massion PP, Taflan PM, Shyr Y, Rahman SMJ, Yildiz P, Shakthour B, Edgerton ME, et al. (2004) Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 170:1088–1094 Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S (2004) Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103:307–312 Prento P, Lyon H (1997) Commercial formalin substitutes for histopathology. Biotech Histochem 72:273–282[Medline] Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, et al. (2006) Pharmacodynamic studies of Gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 24:4309–4316 Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, et al. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with Dasatinib. Mol Cancer Ther 5:3014–3022 Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, et al. (2007) Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 18:1043–1050 Warmington AR, Wilkinson JM, Riley CB (2000) Evaluation of ethanol-based fixatives as a substitute for formalin in diagnostic clinical laboratories. J Histotechnol 23:299–308 Weinberg RA (2007) The Biology of Cancer. New York, Garland Science Williams JH, Mepham BL, Wright DH (1997) Tissue preparation for immunocytochemistry. J Clin Pathol 50:422–428 Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signaling network. Natl Rev 2:127–137[CrossRef] Zhang Z-Q, Notermans DW, Sedgewick G, Cavert W, Wietgrefe S, Zupanic M, Gebhard K, et al. (1998) Kinetics of CD4 T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci USA 95:1154–1159 Zhang Z-Q, Schuler T, Cavert W, Notermans DW, Gebhard K, Henry K, Havlir DV, et al. (1999a) Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc Natl Acad Sci USA 96:5169–5172 Zhang Z-Q, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA, et al. (1999b) Sexual transmission and propagation of SIV and HIV in resting and activated CD4 T Cells. Science 286:1353–1357 Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, Thompson JF, et al. (2005) Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 58:1163–1169
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||